Icon

UNASYN (nda050608)- (EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL,EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL,EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL,EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL)

AMPICILLIN SODIUM; SULBACTAM SODIUM PFIZER
EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL,EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL,EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL,EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL
No No
Expired Expired
None None
None No
UNASYN is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. *Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, Klebsiella spp. (including K. pneumoniae), Proteus mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus. *Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae), Bacteroides spp. (including B. fragilis), and Enterobacter spp. *Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and Bacteroides spp. (including B. fragilis).
20 0 15
Total Other Developers 1
Drugs with Suitability No
EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL ** ** - - -
EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL ** ** - - -
EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL ** ** - - -
EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 13
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***
****** *** ****** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ***** ****** ******* ********* ****** ******* *********** ****-***, **.**.***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ***** ****** ******* ******** ****** ******* ******* *** *********** ****-*, **** **. **-**,**-**,**,**,***,*** *.*.*., ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** ******* ***** *** ******* ******* *********** ** **: *** ** ***, *** ** ***, *** ** ***, *** ** ***, *****, ***, **** **: *-*/*, *-* & *-*, ********* *******, ********* ******, ************, ********* ******, ***** (***) ***
****** ***** ****** ******* ******** ****** ******* ******* *** *********** ****-*, **** **. **-**,**-**,**,**,***,*** *.*.*., ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** ******* ********* ****** ******* *********** ****-***, **.**.***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ****** ****** ********* ******* ******* *********** ***, *.*.*.*., *********, ********, ******* ******, ***** (***) ***
****** ************ ******* ***** ************ ******* *********** (***), **** **. ***-*, *********** ****** **** ****, ********** ****, ****** *****, *********, ********* ******, ***** (***) ***
****** ************ ******* ************ *********** ******* ******* *********** **** ****** ********, ***/* & ***/**, *************, ***********, ************ ****,, *********, ********* ******, ***** (***) ***
****** *********** *********** ** *********** * ***** ******* ******, ****, **** ******, ******* (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***
****** *** ****** ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ***** ****** ******* ***** *** ******* ******* *********** ** **: *** ** ***, *** ** ***, *** ** ***, *** ** ***, *****, ***, **** **: *-*/*, *-* & *-*, ********* *******, ********* ******, ************, ********* ******, ***** (***) ***
****** ***** ****** ******* ******** ****** ******* ******* *** *********** ****-*, **** **. **-**,**-**,**,**,***,*** *.*.*., ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ***** ****** ******* ********* ****** ******* *********** ****-***, **.**.***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ****** ****** ********* ******* ******* *********** ***, *.*.*.*., *********, ********, ******* ******, ***** (***) ***
****** ************ ******* ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.